EXELON Drug Profile

Name: rivastigmine
Brand: EXELON

« Back to Dashboard

Which patents cover Exelon, and what generic Exelon alternatives are available?

Exelon is a drug marketed by Novartis and is included in three NDAs. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.

Summary for Tradename: EXELON

Patents:	2
Applicants:	1
NDAs:	3
Suppliers / Packagers: see list	5
Bulk Api Vendors: see list	45
Clinical Trials: see list	10
Patent Applications: see list	4,407
Formulation / Manufacturing:	see details
Drug Prices:	see details
DailyMed Link:	EXELON at DailyMed

Pharmacology for Tradename: EXELON

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

ADD ALERT

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Exclusivity Expiration
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-003	Apr 21, 2000	AB	RX	Yes	Yes		► Subscribe		► Subscribe
Novartis	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007	AB	RX	Yes	No	6,316,023	► Subscribe	Y	► Subscribe
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-006	Apr 21, 2000	AB	RX	Yes	Yes		► Subscribe		► Subscribe
Novartis	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	AB	RX	Yes	Yes	6,316,023	► Subscribe	Y	► Subscribe
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-004	Apr 21, 2000	AB	RX	Yes	No		► Subscribe		► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

Anticipate P&T budget requirements
Predict branded drug patent expiration
Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

Available with subscription

Paragraph IV Activity

Available with subscription

Patent Maintenance

Available with subscription

Non-Orange Book Patents

Available with subscription

International Patents

Available with subscription

Supplementary Protection Certificates

Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

EXELON Drug Profile

« Back to Dashboard

Summary for Tradename: EXELON

Pharmacology for Tradename: EXELON

Glossary

Subscribe for Complete Access

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Get our Free Drug Patent Bulletin